New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2014
07:46 EDTFPRXFive Prime price target raised to $20-$22 from $17-$19 at Wells Fargo
Wells Fargo increased its price target on Five Prime as the firm thinks the company's novel immunotherapy treatment targets have significant potential, and will likely enable the company to sign a partnership in the near-term. The firm continues to believe that the stock does not adequately reflect the company's long-term potential, and it keeps an Outperform rating on the shares.
News For FPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
09:00 EDTFPRXBristol-Myers, Five Prime announce clinical collaboration for Opdivo, FPA008
Subscribe for More Information
November 17, 2014
16:54 EDTFPRXFive Prime initiates dosing of RA patients in FPA008 Phase 1 clinical trial
Five Prime Therapeutics discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company has initiated dosing of rheumatoid arthritis, or RA, patients in its Phase 1 clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor, or CSF1R. FPA008 is being developed as a potential treatment for RA and solid tumors. FPA008 has two modes of action in RA, blocking the production of multiple inflammatory cytokines and directly inhibiting the activity of osteoclasts, thus preventing bone erosion.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use